Diagnosis, Classification, and Management of Myocarditis
A novel framework defines myocarditis severity based on presence of risk factors, symptoms, and structural/functional abnormality:
CMR with T1/T2 parametric mapping and endomyocardial biopsy (EMB) are considered pivotal tests. The Updated Lake Louise Criteria (2018) require ≥1 T2-based AND ≥1 T1-based criterion for myocarditis diagnosis on CMR.
Myocarditis stages correlate with clinical trajectory. Stage D myocarditis with hemodynamic/electrical instability requires urgent referral to an advanced HF center with mechanical circulatory support capability.
Consensus indications for immunosuppressive therapy now explicitly include eosinophilic, giant cell, granulomatous, and immune checkpoint inhibitor (ICI)-associated myocarditis, with evolving evidence for viral myocarditis.
Athletes with myocarditis should abstain from competitive sports and strenuous activity for ≥3–6 months; clearance requires resolution on CMR and normal stress testing.
Stage B (Asymptomatic Myocarditis)
Elevated hs-cTn or CMR evidence of myocardial inflammation; clinical presentation NOT consistent with acute myocarditis. May be detected incidentally during screening or workup for other conditions.
Stage C (Symptomatic Myocarditis)
Classic presentations (chest pain, arrhythmia, HF, syncope) with diagnostic evidence on CMR or EMB. Manifestations range from isolated chest pain to fulminant cardiogenic shock.
Stage D (Advanced Myocarditis)
Hemodynamic instability (reduced systolic BP, elevated filling pressures, cardiogenic shock) or electrical instability (sustained VT/VF, high-grade AV block) requiring inotropic or temporary circulatory support, or urgent intervention.
Histologically defined by multinucleated giant cells on EMB; typically presents with fulminant course, rapid hemodynamic deterioration, and high mortality without transplant. Requires aggressive immunosuppression and mechanical support.
Three classic presentations of myocarditis:
Arrhythmia (palpitations, syncope, presyncope, sudden cardiac death risk; ECG may show ectopy or malignant patterns)
Heart Failure / Cardiogenic Shock (new or worsening HF, dyspnea, fatigue, hemodynamic instability)
Prodromal clue: Antecedent viral infection (upper respiratory, gastrointestinal), autoimmune condition, family history of cardiomyopathy, or unexplained sudden death in a young relative.
Assess for need of hospitalization, urgent referral to advanced HF center, or emergent arrhythmia/hemodynamic support:
Cardiac Magnetic Resonance (CMR) with T1 and T2 parametric mapping is the gold standard for noninvasive diagnosis in stable patients.
Endomyocardial Biopsy (EMB) is considered in Stage B (uncertain diagnosis), Stage C (LV dysfunction/HF/arrhythmia), or Stage D (advanced), and for suspected high-risk histologies.
Myocarditis is diagnosed if ≥1 T2-based AND ≥1 T1-based criterion is present:
PLUS ONE T1-BASED CRITERION:
| CMR Parameter | Finding | Interpretation |
|---|---|---|
| T1-weighted imaging | Hyperenhancement (bright myocardium) | Edema; increased myocardial water content indicating acute inflammation |
| T1-map (native) | Increased T1 relaxation time | Edema; quantifies myocardial inflammation |
| T2-weighted imaging | Increased T2 signal | Edema; reflects myocardial inflammation |
| T2-map | Elevated T2 relaxation time | Quantitative edema assessment; more specific than T2W |
| LGE (Late Gadolinium Enhancement) | Nonischemic pattern (midwall, subepicardial) | Myocardial fibrosis, scar; prognostic significance; may indicate myocyte necrosis |
| ECV (Extracellular Volume) | Increased ECV fraction | Expands extracellular space; reflects edema and fibrosis |
Technical challenges: Breath-hold artifacts, motion, patient factors; quality control and protocol standardization critical for accurate diagnosis.
Avoid EMB if:
| Histologic Category | Features | Etiology |
|---|---|---|
| Active Myocarditis | Inflammatory infiltrate (T cells, macrophages) + myocyte necrosis | Viral, autoimmune, ICI-related |
| Borderline Myocarditis | Minimal inflammatory infiltrate, no myocyte necrosis | Early/resolving disease or artifact |
| Healing/Resolved | Fibrosis without active inflammation | Remote or chronic inflammation |
| Giant Cell Myocarditis | Multinucleated giant cells + lymphocytic infiltrate | Idiopathic (autoimmune etiology presumed) |
| Eosinophilic Myocarditis | Prominent eosinophil infiltration | Drug hypersensitivity, parasites, HES |
| Granulomatous | Noncaseating granulomas | Sarcoidosis, TB, fungal infection |
IHC panels (anti-CD3, CD4, CD8, CD68, HLA-DR) characterize inflammatory cell types and infiltrate burden; helps identify immune-dominant phenotypes (T-cell vs. macrophage-predominant) and guides therapy selection (e.g., GCM with CD3+ predominance).
Agents: Adenovirus, enterovirus, parvovirus B19, EBV, CMV, herpes simplex, SARS-CoV-2
Pathophysiology: Direct viral myocytolysis vs. immune-mediated injury through molecular mimicry and bystander activation
Management: Supportive care; antivirals if active documented infection; avoid NSAIDs and high-intensity exercise during acute phase
Conditions: SLE, rheumatoid arthritis, vasculitis, sarcoidosis
Recognition: Systemic symptoms, elevated inflammatory markers, positive autoimmune serologies
Management: Immunosuppression per rheumatology/specialty input; disease-specific therapy
Incidence: 0.1–1.6% across series; fulminant presentation common (>50% develop hemodynamic instability)
Timing: Median onset ~2–3 weeks after checkpoint inhibitor initiation; range from days to months
Risk factors: Combination ICI therapy (anti-PD-1 + anti-CTLA-4), prior cardiotoxic therapy, underlying systemic autoimmunity
CTCAE v5 Grading:
Management: ICU admission; immediate high-dose IV methylprednisolone (1 g × 3 days) → oral prednisone taper; additional immunosuppression (mycophenolate, tacrolimus, IVIG) if inadequate steroid response; consider holding checkpoint inhibitor
Checkpoint inhibitor rechallenge: Only after full recovery (imaging + clinical normalization); multidisciplinary discussion required (oncology, cardiology, immunology)
Presentation: Fulminant course; hemodynamic instability, VT/VF, rapid progression to HF; ~50% present with cardiogenic shock
Prognosis: Poor without aggressive therapy; median survival <6 months without transplant; >50% survival at 1 year with transplant
Management:
Dobutamine, milrinone: Reserved for temporary bridge to recovery or mechanical support; avoid as long-term monotherapy. Provides temporary cardiac output augmentation in low-output states.
LVAD (Left Ventricular Assist Device — Durable): Bridge to transplant or destination therapy if no recovery in 6–12 months; consider for Stage D failing medical/mechanical therapy
Temporary percutaneous support: Impella, IABP for short-term hemodynamic stabilization; step-up to durable support if needed
Transplant consideration: Early discussion with advanced HF/transplant team for Stage D patients; 27–35% mortality despite MCS in some cohorts
| Drug Class | Agent | Indication |
|---|---|---|
| ACEi / ARB / ARNI | Lisinopril, enalapril, losartan, valsartan, sacubitril/valsartan | First-line for reduced LVEF; start low, titrate to target dose |
| Beta-blocker | Carvedilol, metoprolol succinate, bisoprolol | All HF stages; cardioprotection; arrhythmia control |
| Aldosterone antagonist (MRA) | Spironolactone, eplerenone | LVEF ≤40%; reduces mortality and HF hospitalizations |
| SGLT2 inhibitor | Dapagliflozin, empagliflozin | HFrEF, HFmrEF; emerging evidence for HFpEF; cardioprotection |
| Diuretic | Furosemide, torsemide, bumetanide | Fluid overload; goal euvolemia |
IV methylprednisolone: 1 g IV daily × 3 days, then oral prednisone 1 mg/kg/day with taper over 4–8 weeks (reduce by 0.1 mg/kg every 5–7 days).
Options: Mycophenolate mofetil (1–3 g/day in divided doses), tacrolimus (target trough 10–15 ng/mL), or IVIG (2 g/kg over 3–5 days)
Serial troponin, CRP, ECG, echocardiography, and CMR to assess response. Most patients show clinical improvement within 1–2 weeks of high-dose steroids; 80% recover without requiring additional immunosuppression.
Only consider after: Full clinical recovery, normalization of troponin/biomarkers, echocardiographic improvement, and imaging (CMR) resolution. Multidisciplinary discussion with oncology/cardiology essential; high-risk approach given 30–50% recurrence rate in some cohorts.
EMB showing multinucleated giant cells + lymphocytic infiltrate is diagnostic. Presentation typically fulminant with hemodynamic instability, life-threatening arrhythmia, and rapid LV dysfunction.
Adjunctive options:
5-year survival: ~50% with dual immunosuppression + heart transplant; <10% with medical therapy alone
Majority of GCM patients require mechanical circulatory support (VA-ECMO, LVAD) during acute phase and for bridge to transplant. Discuss transplant candidacy early; many centers have favorable outcomes if patient can survive to transplantation.
At diagnosis: All patients should abstain from strenuous physical activity and competitive sports for ≥3–6 months minimum. Rationale: viral replication, immune activation ongoing; risk of sudden cardiac death during myocardial inflammation.
Continue abstinence if: Persistent symptoms, arrhythmia, reduced exercise capacity, or abnormal CMR/stress findings; reassess in 3 months.
Athletes with fulminant myocarditis, GCM, or sustained arrhythmias may require longer restriction (6–12 months) or permanent modification of activity level. Individualize based on imaging, arrhythmia burden, and functional recovery.
| Stage | Typical Outcome | Key Prognostic Factors |
|---|---|---|
| A (At-Risk) | Favorable; most never progress to symptomatic disease | Risk stratification; family screening; genetic testing |
| B (Asymptomatic) | Variable; generally favorable if low-risk features | Elevated troponin trajectory; CMR extent; age |
| C (Symptomatic) | ~50% fully recover within 2–4 weeks; ~25% persistent dysfunction; ~12–25% deteriorate | LVEF at presentation; LGE presence/extent; histology; ventricular arrhythmias |
| D (Advanced) | High mortality (27–35%) without transplant; >50% survival at 1 year with transplant | Fulminant presentation; shock at admission; mechanical support requirement |
Approximately 1/3 of myocarditis patients progress to chronic HF (HFmrEF/HFpEF). Close surveillance with serial imaging, biomarkers, and functional testing recommended; genetic counseling and testing for familial cases.
The following calculators complement clinical decision-making in myocarditis and HF management:
Predicts 1, 3, and 5-year mortality in patients with chronic HF; useful for prognostication and transplant discussions.
Helps optimize guideline-directed medical therapy dosing and sequencing in HF; supports stepwise titration.
Risk stratifies patients for mechanical circulatory support urgency; guides MCS timing and device selection.
Stratifies cardiogenic shock severity and guides hemodynamic support strategy (inotropes, MCS, transplant).
Calculates QTc to assess drug-induced QT prolongation and arrhythmia risk in myocarditis patients on immunosuppression.
Estimates glomerular filtration rate to guide medication dosing in myocarditis patients with renal involvement.
Calculates renal clearance for drug dosing adjustments in renal dysfunction.
Estimates stroke risk in patients with atrial fibrillation complicating myocarditis; guides anticoagulation decisions.
Rationale: Reduces afterload, prevents remodeling, improves survival in HF. Start low-dose, titrate gradually to avoid hypotension (common in acute myocarditis).
Common agents: Lisinopril 2.5–5 mg daily; ramipril 2.5 mg daily; losartan 25–50 mg daily; valsartan 40–80 mg daily; sacubitril/valsartan 24/26 mg daily (ARNI preferred in reduced EF).
Monitoring: Baseline and follow-up K+, creatinine; expect transient increase in creatinine (~20%); avoid if systolic BP <90 mmHg or K+ >5.5 mEq/L.
Preferred agents: Carvedilol (nonselective + alpha-blocker; 3.125–25 mg daily), metoprolol succinate extended-release (25–190 mg daily), bisoprolol (1.25–10 mg daily).
Avoid: Immediate-release metoprolol, atenolol, propranolol (less favorable in HF).
Titration: Start low; double dose every 2 weeks if tolerated; goal heart rate 50–60 bpm (lower in acute myocarditis often acceptable).
Caution: Avoid abrupt discontinuation; taper slowly if stopped. Hypotension and bradycardia common early; usually improve with time.
Indications: LVEF ≤40%; improves survival, reduces hospitalizations. Start spironolactone 12.5–25 mg daily or eplerenone 25 mg daily.
Monitoring critical: Baseline K+ <5.0 mEq/L; recheck at 3–7 days, 1 month, then periodically. Hyperkalemia risk increased if renal dysfunction, on ACEi/ARB, or NSAIDs used.
Goal: Target dose spironolactone 25–50 mg daily (higher doses not recommended in acute myocarditis).
Agents: Dapagliflozin 10 mg daily, empagliflozin 10 mg daily. Improve HF symptoms, reduce hospitalizations; mechanism partially independent of glucose control.
Timing: Can start early in acute phase if hemodynamically stable; particularly beneficial in HFmrEF/HFpEF phenotypes emerging in myocarditis.
Caution: Monitor for euglycemic DKA (rare; watch for nausea, dyspnea, normal glucose); avoid in acute decompensation.
Goal: Euvolemia (no orthopnea, peripheral edema, elevated JVP). Use loop diuretics (furosemide, torsemide, bumetanide) as needed; switch to lower dose once euvolemic.
Monitoring: Daily weights; watch for hypokalemia, hyponatremia; adjust electrolytes as needed. Avoid excessive diuresis (worsens renal function, activates RAAS).
Pathophysiology update: Viral replication occurs in early phase (~7–10 days); immune phase follows with T-cell and macrophage infiltration. This explains why antivirals have limited benefit if started late.
Specific viral therapies: No proven role for routine antivirals in viral myocarditis. In rare cases of documented active viral replication (PCR-positive EMB, advanced immune testing), consider consultant input from infectious disease. IVIG not routinely recommended for viral myocarditis.
Natural history: Most viral myocarditis self-limited; ~50% fully recover within 2–4 weeks. Avoid NSAIDs (may worsen outcome). Colchicine for pericarditis component if present.
SLE myocarditis: Treat underlying SLE with hydroxychloroquine, corticosteroids ± immunosuppression (azathioprine, mycophenolate, IVIG). Cardiac-specific therapy as per HF guidelines.
Rheumatoid arthritis: Continue or initiate DMARDs (methotrexate, biologic TNF inhibitors); immunosuppression guided by rheumatology. Myocarditis may improve with DMARD therapy.
Vasculitis-associated: Treat underlying vasculitis (corticosteroids, cyclophosphamide, rituximab per rheumatology/pulmonology); cardiac support as needed.
Sarcoidosis with cardiac involvement: Prednisone ± calcineurin inhibitor (cyclosporine or tacrolimus) ± mycophenolate. ICD for conduction abnormalities/arrhythmia. Collaborate with pulmonology for systemic sarcoidosis management.
Grade 1 (asymptomatic): Hold checkpoint inhibitor pending workup (EMB/CMR); close monitoring; consider steroids if troponin elevated or imaging abnormal.
Grade 2–3 (symptomatic): Hospitalize; IV methylprednisolone 1 g × 3 days (high-dose pulse); transition to oral prednisone 1 mg/kg/day taper. Most respond (80%+) to steroids alone; reassess at 1–2 weeks.
Grade 4 (fulminant/life-threatening): ICU admission; IV methylprednisolone 1 g × 3 days; simultaneous dual therapy with mycophenolate (MMF 1–3 g/day divided) or tacrolimus (target trough 10–15 ng/mL); IVIG (2 g/kg) if no improvement in 48–72 hours; mechanical support (ECMO, LVAD) for refractory shock.
Checkpoint inhibitor rechallenge decision-making: Involves oncology, cardiology, and immunology. Risk-benefit analysis: reintroduction may improve cancer outcome but risks recurrent myocarditis (30–50% recurrence rate reported). Most centers recommend against rechallenge unless cancer prognosis dire and alternate therapies exhausted.
Standard induction: IV methylprednisolone 1 g daily × 3 days, then oral prednisone 60 mg daily (1 mg/kg) with slow taper (reduce 10 mg/week over 3–4 months).
Calcineurin inhibitor selection: Cyclosporine preferred (target trough 200–300 ng/mL) over tacrolimus based on observational data suggesting superior outcomes. Monitor baseline and periodic levels; baseline renal function, K+, magnesium.
Maintenance (after acute phase): Prednisone taper to 0.5 mg/kg/day (or lower) over 6–12 months; cyclosporine continued at maintenance doses ± mycophenolate (1–3 g/day) as adjunct.
Monitoring during therapy: Weekly labs (CBC, CMP, tacrolimus/cyclosporine levels) first month; monthly thereafter. Assess for infections, renal toxicity, hypertension, hyperglycemia. Prophylax PCP pneumonia (TMP-SMX).
Transplant discussion: GCM is indication for early transplant evaluation. Median survival <6 months without transplant; >50% 1-year survival with transplant achieved at experienced centers. Consider LVAD/ECMO bridge if no immediate donor availability.
Identify & remove trigger: Discontinue suspected medications (antibiotics, anticonvulsants, allopurinol, NSAIDs). Avoid re-exposure.
Corticosteroid therapy: Prednisone 0.5–1 mg/kg/day × 1–2 weeks, then taper. Most cases respond rapidly (days–weeks) to steroids; discontinuation after 4–8 weeks if clinical/laboratory improvement and eosinophilias normalizes.
Refractory cases: Calcineurin inhibitor (cyclosporine) or mycophenolate (1–3 g/day) for steroid-resistant eosinophilic myocarditis. IVIG (2 g/kg) if life-threatening arrhythmia or shock.
Follow-up: Serial CBC; watch for recurrent eosinophilia (suggests incomplete medication withdrawal or alternative diagnosis like HES).
Diagnostic confirmation: Noncaseating granulomas on EMB ± elevated ACE/hypercalcemia; PET imaging helpful for disease burden.
Immunosuppression: Prednisone 0.5–1 mg/kg/day with slow taper over 3–6 months. Calcineurin inhibitor (cyclosporine, tacrolimus) or mycophenolate for steroid-sparing or adjunctive effect.
ICD/pacemaker:** Essential if conduction abnormalities (high-degree AV block), symptomatic bradycardia, or nonsustained/sustained VT. Basal septal LGE pattern on CMR associated with arrhythmia risk.
Pulmonary/extracardiac sarcoidosis:** Coordinate care with pulmonology; ensure systemic sarcoidosis treatment optimized. Cardiac involvement worse prognosis in systemic sarcoidosis.
Recognition: Athletes often present with minimized symptoms due to fitness; maintain high index of suspicion in young, previously healthy individuals with new chest pain, dyspnea, or syncope.
Return-to-play strategy: Gradual, stepwise progression after clearance. Begin with light aerobic activity (walking/jogging) at week 4–6 post-diagnosis if asymptomatic; progress to moderate intensity (running, cycling) by week 8–12; resume competitive sports only after documented normalization on imaging and stress testing (typically 3–6 months).
Pathophysiology: Immune-mediated inflammation; higher incidence in third trimester and early postpartum period; additional hemodynamic stress of pregnancy/postpartum may unmask subclinical disease.
Diagnosis: Echocardiography and biomarkers safe; CMR feasible with gadolinium (Category C, generally considered safe if benefit outweighs risk); avoid EMB unless diagnosis critical for management.
Management: GDMT (ACEi/ARB/ARNI, beta-blockers, MRA) contraindicated in pregnancy; switch to labetalol, nifedipine, or hydralazine. Consider temporary hemodynamic support if unstable; mode and timing of delivery tailored to maternal/fetal status.
Presentation: Highly variable; may present with acute shock (fulminant forms), subtle symptoms (viral prodrome), or incidental finding on screening. Viral triggers common (enterovirus, parvovirus B19).
Management differs from adults: Many pediatric cases self-limited and resolve without specific therapy; immunosuppression data sparse; supportive care and GDMT mainstay; mechanical support bridge to recovery more common than transplant.
Genetic counseling: Important in pediatric cases; screening of siblings and parents recommended if familial cardiomyopathy suspected.
Nonsustained VT (NSVT): Common in acute myocarditis; does not necessarily warrant ICD placement in the acute phase. Serial ECG/Holter monitoring and follow-up imaging guide decision.
Sustained VT/VF: Requires urgent ICD placement; consider temporary pacing/mechanical support if hemodynamically unstable.
High-degree AV block: Temporary pacing indicated if hemodynamically significant; usually resolves in acute myocarditis as inflammation improves.
Timing: ICD placement typically deferred in acute phase; reassess after 6 weeks–3 months of recovery. Many myocarditis patients show electrical restitution and no longer meet ICD criteria after healing.
Indication: LVEF ≤35% despite GDMT × 40 days ± recurrent sustained VT/VF; EF recovers in ~75% of acute cases, potentially eliminating ICD need.
Wearable cardiac defibrillator (WCD) offers bridging protection during initial recovery phase, allowing reassessment of arrhythmia risk before permanent ICD. Emerging evidence supports WCD use in acute myocarditis pending EF recovery.
Serial hs-cTn: Elevated levels at baseline; serial measurements to track decline (prognostic marker). Persistently elevated troponin suggests ongoing inflammation or recurrence.
CRP / inflammatory markers: Support assessment of disease activity; normalize with recovery.
Myocarditis remains a diagnostic and therapeutic challenge requiring high clinical suspicion and multimodal testing (hs-cTn, ECG, echocardiography, CMR, EMB). The novel 4-stage classification framework helps risk-stratify patients and guide therapy intensity.
CMR with Lake Louise Criteria (2018) is the noninvasive gold standard; EMB is reserved for high-risk presentations, uncertain diagnoses, and specific etiologies.
Immunosuppression is now consensus-supported for eosinophilic, giant cell, granulomatous, and ICI-related myocarditis. High-dose corticosteroids with or without calcineurin inhibitors offer improved outcomes in select populations.
Timely referral to an advanced HF center is critical for Stage D myocarditis and fulminant presentations to enable access to mechanical circulatory support and transplant evaluation.
Long-term follow-up with serial imaging and biomarkers enables detection of progression, guides therapy optimization, and supports return-to-activity counseling in athletes and active patients.
Risk stratification and individualized management based on stage, etiology, and imaging findings optimize outcomes. Even fulminant myocarditis with appropriate early intervention can achieve recovery or successful transplantation.
Reference: Drazner MH, et al. 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. J Am Coll Cardiol. 2025;85(4):391–431. doi: 10.1016/j.jacc.2024.10.080